IMR Press / EJGO / Volume 26 / Issue 5 / pii/2005223

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Open Access Original Research

Ingenol derivatives inhibit proliferation and induce apoptosis in breast cancer cell lines

Show Less
1 Department of Obstetrics and Gynaecology, Amedeo Avogadro University of Eastern Piedmont, Novara (Italy)
2 Department of Pharmaceutical Technologies and Sciences, Amedeo Avogadro University of Eastern Piedmont, Novara (Italy)
Eur. J. Gynaecol. Oncol. 2005, 26(5), 526–530;
Published: 10 October 2005
Abstract

We present an analysis of the antitumour effects of a library of ingenol derivatives synthesized in our laboratory and published elsewhere. Fluoro-ingenol (1), ingenol-20-deoxy-20-phtalimido (2), ingenol-3-benzoate-20-deoxy-20-benzamide (3), ingenol-3- benzoate (4), ingenol-3,5-dibenzoate (5), ingenol-3,20-dibenzoate (6), 20-deoxy-20-benylureidoingenol-3-benzoate (7), ingenol-20- deoxy-20-fluoro-3-benzoate (8), ingenol-20-deoxy-20-fluoro-3,5- dibenzoate (9), ingenol-20-phenylcarbamate (10), ingenol-20-ben­zoate (11), ingenol-3-benzoate-20-phenylcarbamate (12) were tested in vitro on two well characterized breast cancer cell (BCC) lines, namely T 4 7D and MDA-MB-231, as representative of two opposite types of hormone-sensitiveness and differentiation stage. These experiments led us to identify ingenol-20-benzoate (11) as a promising anti tumour compound characterized by a relevant inhibition of cell growth and apoptotic cell death involving a p53-mediated pathway.

Keywords
Apoptosis
Breast cancer
Chemotherapy
Ingenol
PKC
Share
Back to top